Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
|
|
- Rudolf Potter
- 5 years ago
- Views:
Transcription
1 Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28, Foley Hoag LLP. All Rights Reserved.
2 Panelists Wendy Tsai, Founder and VP Alliances, Cellona Therapeutics Julia C. Owens, Senior V.P. Corporate Development and Strategy, Lycera Gregory Miller, Head, Business & Corporate Development, CoNCERT Pharmaceuticals Hemmie Chang, Chair, Licensing & Strategic Alliances Group, Partner, Foley Hoag LLP 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 2
3 Wendy Tsai Cellona Therapeutics Mission: Develop targeted therapeutics to improve survival paradigms in cancer patients. Strengths: Management team has an extensive and successful track record in the critical elements of Cellona s business model. Pioneering science and robust patents. Milestone-driven corporate planning with non-dilutive seed capital from government QTDP grant; foundation and angels. Partnering Strategy: Academic collaboration 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 3
4 Julia Owens - Lycera Mission: Discovery and development of first-in-class oral medications to treat patients with serious immune diseases for which existing therapies are inadequate. Strengths: Experienced and accomplished leadership and scientific teams with core capabilities in discovery research, medicinal chemistry and early development. $36 million Series A financing. Significant research collaboration with Merck. Partnering Strategy: Big Pharma 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 4
5 Gregory Miller CoNCERT Pharmaceuticals Mission: Applying DCE Platform (deuterated chemical entity platform) to create novel, differentiated drugs. Strengths: Successful clinical demonstration achieved. Rapid progression from initial synthesis to clinic. Broad patent estate and intellectual property position. Strong financial position over $110 million raised. Partnering Strategy: Pharma and Government, with parallel development of unpartnered programs 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 5
6 Licensing Trends: Recent Deal Activity Licensing Deals With >$10M Upfront Payment Source: EBI Transaction Tracker, Accessed November 11, 2010 and October 30, Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 6
7 Challenging Environment for Early Stage Funding Life sciences funding by stage Why did your company delay R&D 2011? Source: PricewaterhouseCoopers, Zigzagging upward, February 2012 Source: California Biomedical Industry 2012 Report 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 7
8 Expanding Base of Early Stage Investors 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 8
9 Financing Trends: Positioning for Success DE-RISKED ASSETS VC INCUBATED CAPITAL EFFICIENT, VIRTUAL MODEL SYNDICATED RISK PHARMA PARTNERSHIP EARLY STAGE DEAL ROBUST R&D PIPELINE 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies v2
10 Licensing Deal Term Trends: Up-fronts Millions ($) Source: Elsevier s Strategic Transactions. Data set includes 299 alliances by big pharma, mid-sized European companies, top Japanese, and big biotech for which upfronts were disclosed Phase II average skewed by mammoth Abbott/Reata deal; if excluded average drops to $38.3mm Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 10
11 Evaluating Potential Partnerships Some overlapping priorities: Exclusivity Upfront and nearterm milestones Retain profit share option Partner with resources, marketing expertise Shared vision Scientific alignment Innovation Diverse partners Complementary program to internal R&D Ability to make rapid progress SMALL INNOVATOR POTENTIAL PARTNER 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 11
12 Process of Seeking a Collaboration???? Royalties Upfront payments Milestone payments Profit share option Timing Ownership of IP Control 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 12
13 Going From Early Stage to the Next Stage Develop technology Raise $110M $1B strategic alliance 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 13
14 Developing Diverse Pipeline in Parallel Research Development Development Programs CTP-499: Diabetic Nephropathy (anti-inflammatory/anti-fibrotic/anti-oxidant) CTP-298: HIV (protease inhibitor) Select Research Programs C-21191: Spasticity, Pain C-10003: Pain, PBA C-10068: Epilepsy, Depression C-21359: Hematological Cancers Research Preclinical Phase I Phase 2 C-10291: Narcolepsy, Fibromyalgia D-Praziquantel: Schistosomiasis 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 14
15 Thinking About Exit: What s Pharma Buying? Source: Elsevier s Strategic Transactions 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 15
16 VCs: In which industries do you expect to see investment froth in 2012? Biopharma Source: National Venture Capital Association and DowJones Venture Source, Venture View 2012: Venture Capital Industry Predictions, December Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 16
17 Final thoughts from our panel Wendy Tsai, Founder and VP Alliances, Cellona Therapeutics Julia C. Owens, Senior V.P. Corporate Development and Strategy, Lycera Gregory Miller, Head, Business & Corporate Development, CoNCERT Pharmaceuticals Hemmie Chang, Chair, Licensing & Strategic Alliances Group, Partner, Foley Hoag LLP 2012 Foley Hoag LLP. All Rights Reserved. Perspectives of Innovative Small Companies 17
State of Licensing 2011 Update
State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationNektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationwhen it comes to law OPERATIONAL EXPERIENCE Soody Tronson Managing Founder Phone Fax Woodside / Santa Clara
when it comes to law Soody Tronson Managing Founder OPERATIONAL EXPERIENCE soody@stlgip.com Phone 650.275.3913 Fax 866.325.7964 Woodside / Santa Clara www.stlgip.com matters By appointment only https://calendly.com/soody
More informationPwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationFinancing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics
1 Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics Eric Dobmeier Chief Business Officer Life science startups are the only companies that are forced to define their
More informationFinancing Growth Ventures to Minimize Equity Dilution
Financing Growth Ventures to Minimize Equity Dilution An entrepreneurial team s mission is to develop and grow its venture and to optimize the management team s equity ownership stake. Significant growth
More informationDiscovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationManaging Intellectual Property Assets: The NIH OTT Perspective
2009/SOM1/IPEG/SEM/003 Session: 2 Managing Intellectual Property Assets: The NIH OTT Perspective Submitted by: United States From Mind to Market: The Highs and Lows of Technology Transfer Singapore 23-24
More informationFinancing Emerging Growth Companies
Financing Emerging Growth Companies July (8,15,22) 2005 Ravi Sinha/Wilson Zehr Portland State University School of Business July 8, 2005 1:00 1:50 Class overview, review syllabus, grading, case studies
More informationIntellectual Property Management Medicines for Malaria Venture. Life Sciences Symposium WIPO 15 December 2008
Intellectual Property Management Medicines for Malaria Venture Life Sciences Symposium WIPO 15 December 2008 1 Structure of the presentation 1. MMV at a glance - PPP model 2. MMV and Intellectual Property
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationNVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
More informationResearch Patents in Biotech SMEs
Research Patents in Biotech SMEs Doorways, Obstacles, Fortifications & Bridges Neil Thomas PhD Director of Intellectual Property, Genetrix Group, Madrid, Spain. Agenda 1. Introduction to Genetrix Definition
More informationPharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment
Presenter: Randall Sunberg Morgan Lewis May 16, 2008 In cooper Biography Randall Sunberg partner Morgan Lewis, Princeton Phone: 609.919.6606 Randall B. Sunberg is a partner in Morgan Lewis's Business and
More informationFounder Follies. Presentation for Harvard Business School. February 9, Jeffrey L. Quillen Alexander J. Aber
Founder Follies Presentation for Harvard Business School February 9, 2012 Jeffrey L. Quillen Alexander J. Aber 2012 Foley Hoag LLP. All Rights Reserved. These materials have been prepared solely for educational
More informationIntellectual Property Policy. DNDi POLICIES
Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments
More informationAn Experienced Approach to Private Equity
An Experienced Approach to Private Equity Monument MicroCap Partners, LLC (MMP) is an independent private investment firm comprised of highly experienced and accomplished private equity and operational
More informationReinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
More informationScripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
More informationWhere the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes
Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes Scientific innovation is at the heart of everything we do. Scientific innovation is at the heart of our business and
More informationSeptember 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board
AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT
More informationAgenda. Genesys Capital Partners. The Opportunity. Our Approach
MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience
More informationTransferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research
Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research UCLA Research: A Winning Environment $811M+ in research awards for FY2006 3,300
More informationMedtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year
www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for
More informationexecutives are often viewed to better understand the merits of scientific over commercial solutions.
Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for
More informationPartnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc.
Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc. LIFE SCIENCES LAW, PLLC Prepared for Carolina Innovations Seminar The Office of Technology Development at The University
More informationFall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE
Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number
More informationManagement to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
More informationMixed Signals: Understanding the Outlook for Pharma R&D Spending Through
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,
More informationEmcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationCommercialization Strategies that Work
Commercialization Strategies that Work Jenny C. Servo, Ph.D. DAWNBREAKER (585)594-0025 DAWNBREAKER Professional Services firm - Rochester, NY Worked with over 1200 SBIR/STTR firms - Department of Energy,
More informationRoche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd.
Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo 2011 Dr. Axel Braun F. Hoffmann La Roche Ltd. Content Roche Company Profile The IP Department Patent Filings Global Strategy Sales Overview IP
More informationTeresa V. Pahl Partner
Teresa represents clients in all phases and aspects of their businesses. Teresa s expertise includes matters involving general corporate law, securities law and real property law. Teresa works with early-stage
More informationInnovating 4 DSM
Innovating 4 Change @ DSM Lessons from 1995 ~ 2015 Rob Kirschbaum, CEO SakuragiConsult (former VP Open Innovation DSM) Micro MBA, Breukelen, October, 2017 Introduction to Royal DSM Strategy; Emerging Business
More information小心站台空隙. Don Merino Vice President and General Manager, Asia Licensing Sales. December 2, 2011
小心站台空隙 Don Merino Vice President and General Manager, Asia Licensing Sales December 2, 2011 Inventions are Strategic Assets Logos are believed to be trademarks of their respective companies. 2 More Players
More informationCollegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
More informationgellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.
gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.com Summary Personal Diverse, world-class team of top biotech bankers,
More informationCommercialization Workshop Series Commercialization Pathways. April 2, 2015
Commercialization Workshop Series Commercialization Pathways April 2, 2015 Commercialization Workshop Series Commercialization Pathways Commercialization Options Parasight Seikowave Dean Harvey Eric Hauck
More informationCross-Border R&D in China Understanding the Regulatory Challenges
1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,
More informationFinancing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation
30.04.2014 Aitana Peire Venture Valuation Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Information services / Life Sciences
More informationTurning Clinical Ideas into Market Opportunities
Turning Clinical Ideas into Market Opportunities Howard R. Levin, M.D. MDTX Presentation April 4, 2018 25 MIN Goals of Presentation Explain how ideas are moved from academics to industry Explore the issues/difficulties
More informationAcadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationGOALS FOR PRESENTATION
Shubha Ghosh Professor of Law Associate Director, INSITE University of Wisconsin, Madison GOALS FOR PRESENTATION Background Major Issues Policy Concerns 2 My Background PhD in Economics from Michigan and
More informationBiotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
More informationTriton Technology Fund
Triton Technology Fund Presentation to Dean s Engineering Council March 22, 2013 Generate Returns for LPs/GPs Motivation for Fund Catalyze translation of UCSD discoveries for the benefit of society Enable
More informationPANEL DISCUSSION & ROUNDTABLES
LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the
More informationFor personal use only
2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor
More informationSmall Business Investment Companies
Small Business Investment Companies Small Business Investment Companies The economy depends on privately held businesses, and privately held businesses need capital to grow. The SBIC (Small Business Investment
More informationMaking lives better every day. This is UCB
Making lives better every day. This is UCB Kristof, living with axial spondyloarthritis Remi, UCB Inspired by patients. Driven by science. We have a shared ambition to transform the lives of people living
More information9 Vaccine SMEs' Needs
9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with
More informationDigital Medical Device Innovation: A Prescription for Business and IT Success
10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing
More informationBOARD OF DIRECTORS. PETER WEHRLY Chair
BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held
More informationTrends in Healthcare Investments and Exits 2018
Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview
More informationHigher Education Contribution to Health Science Innovation
Scottish University of the Year 2017 Higher Education Contribution to Health Science Innovation Professor Sir Pete Downes Principal, University of Dundee Lead Member for Health, Universities Scotland 28
More informationFor personal use only
ASX ANNOUNCEMENT AGM PRESENTATION SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders. End Contact: Maria Halasz,
More informationColombia on the Frontier of Biomedicine. Zagaya
Colombia on the Frontier of Biomedicine An Intersectorial Meeting for Research, Innovation and Health February 27 & 28, 2012 Hotel Intercontinental, Cali, Colombia Kay Monroe, Executive Director Zagaya
More informationWPI Intellectual Property A day in the life of the tech transfer office. Todd Keiller Director, Intellectual Property and Innovation
WPI Intellectual Property A day in the life of the tech transfer office Todd Keiller Director, Intellectual Property and Innovation Who does research? Federal and state governments Defense, public health,
More informationMayo Clinic Ventures. Developing, Commercializing and Funding Mayo Clinic Discoveries. Dan Estes MFMER slide MFMER slide-1
Mayo Clinic Ventures Developing, Commercializing and Funding Mayo Clinic Discoveries Dan Estes 2015 MFMER slide-1 2015 MFMER slide-1 Mayo Clinic Ventures (MCV) primary goals Facilitate the translation
More informationLife Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research
Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationTechnology Commercialization Primer: Understanding the Basics. Leza Besemann
Technology Commercialization Primer: Understanding the Basics Leza Besemann 10.02.2015 Agenda Technology commercialization a. Intellectual property b. From lab to market Patents Commercialization strategy
More information56 The Milken Institute Review
56 The Milken Institute Review tk Financing High-Risk Medical Research A Proposal from FasterCures By Melissa Stevens tk First Quarter 2016 57 In the past few years, the media has showered us with headlines
More informationThelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT. J. Thelander Consulting
Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT J. Thelander Consulting 165 Marlin Mill Valley, CA 94941 jt@jthelander.com jthelander.com +1 415.383.7006 Legal Notice: The Thelander
More informationMENTORS REGULATORY AFFAIRS. Christophe AMIEL Head of Medical Device & Digital, Voisin Consulting Life Sciences STRATEGY/BUSINESS
Hosted by : INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris MENTORS REGULATORY AFFAIRS Christophe Amiel is heading the design and operational implementation of international regulatory strategies as Senior
More informationTechnology Leadership Course Descriptions
ENG BE 700 A1 Advanced Biomedical Design and Development (two semesters, eight credits) Significant advances in medical technology require a profound understanding of clinical needs, the engineering skills
More informationOPEN INNOVATION AS A STRATEGIC MODEL OF MODERN BUSINESS
OPEN INNOVATION AS A STRATEGIC MODEL OF MODERN BUSINESS Nataliia Revutska, Assistant Prof. Taras Shevchenko National University of Kyiv, Ukraine Abstract The paper considers the characteristics of two
More informationChallenging Times: Sustaining Your Business While Waiting for Financing. January 14, 2009
Challenging Times: Sustaining Your Business While Waiting for Financing January 14, 2009 Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
More informationVanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited
More informationEQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES
I. Introduction EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES Authored By Philip N. Krause Two categories of entrepreneurial ventures: Revenue Model Growth Model this is what we are discussing
More informationVENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000
CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN
More informationTrends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp
2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Fenwick fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Survey Intro and Background
More information1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp
1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Fenwick fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Survey Introduction
More informationKaro Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
More informationTechnology Transfer: Working with Industry at MIT. 10 February 2009 Kenneth A. Goldman Manager, Corporate Relations MIT Industrial Liaison Program
Technology Transfer: Working with Industry at MIT 10 February 2009 Kenneth A. Goldman Manager, Corporate Relations MIT Industrial Liaison Program Observations Innovation is key to economic growth; impact
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationCollaborating with the Office of Technology Transfer
Collaborating with the Office of Technology Transfer Todd Sherer, Ph.D. Associate Vice President for Research and Executive Director Office of Technology Transfer Emory Owns Our IP As a condition of employment,
More informationTRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
More informationHow attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners
How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost
More informationMara H. Rogers, Partner Norton Rose Fulbright
Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers
More informationAugust 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio
Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members
More informationDaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector
More informationInterplay of Intellectual Property Rights and Academic - Industry Collaboration to Foster Digital Inclusion
Interplay of Intellectual Property Rights and Academic - Industry Collaboration to Foster Digital Inclusion Louis Masi Strategic Alliances, IBM Corporation 1.914.766.3059, lmasi@us.ibm.com Abstract Intellectual
More informationCannabis Practice Group
Cannabis Practice Group McMillan LLP Vancouver Calgary Toronto Ottawa Montréal Hong Kong Cannabis mcmillan.ca Practice Group 1 Medical cannabis is booming and McMillan is at the forefront of developments
More informationOpen Innovation: What s New? Henry Chesbrough Berkeley Innovation Forum October 30, 2008
Open Innovation: What s New? Henry Chesbrough Berkeley Innovation Forum October 30, 2008 What I ve been doing Lots of talks to promote Open Innovation and Open Business models 54 talks this year, compared
More informationContents. 1 Introduction... 1
Contents 1 Introduction... 1 Part I Startup Funding Sources, Stages of the Life Cycle of a Business, and the Corresponding Intellectual Property Strategies for Each Stage 2 Sources of Company Funding...
More informationStarpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationAbout the awards. Categories. Knowledge Transfer Initiative of the Year Knowledge Transfer Achiever of the Year. Judging panel
2015 The KTI Impact Awards recognise successful commercialisation of Irish State-funded research that translates knowledge and expertise for the wider benefit of our economy and society. The awards also
More informationFINC915 Venture Lab Participating Firms: FALL 2010
FINC915 Venture Lab Participating Firms: FALL 2010 Please Note: The listed firms will consider candidates. Not all firms will eventually offer a position to students. LOCAL FIRMS: I2A Fund Number of slots:
More informationNew York Bar admission (or eligibility to obtain admission promptly) is required.
Job Opportunities To apply to any of the positions send cover letter referencing job opening with resume and salary requirements to info@bryantrabbino.com Senior Level Corporate Finance Attorney We are
More informationBioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market
More informationCorvinus Venture Capital Fund Managing Co.
Government Assisted Venture Capital Funds in Innovation Finance in Hungary Introduction of Corvinus Venture Capital Funds Gábor Herczeg CEO Main Topics Brief Introduction of Corvinus First Innovation Venture
More informationBecton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationINSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH
INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH Sharing Information, Knowledge and Materials Dr. Ashley J. Stevens Executive Director, Technology Transfer Senior Research Associate
More information2010/IPEG/SYM/003 Measures for Encouraging Patent Licensing - INPIT Challenges
2010/IPEG/SYM/003 Measures for Encouraging Patent Licensing - INPIT Challenges Submitted by: Japan Innovating Intellectual Property Exploitation Symposium Sendai, Japan 9 September 2010 September 9, 2010
More informationProf. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ Process by which new innovations flow from the basic research bench to commercial entities and then to public use.
More informationIntellectual property governance and strategic value creation:
Intellectual property governance and strategic value creation: some evidence from European organizations in, pharmaceutical and public research fields Dr. Federica Rossi (rossi.federica@unito.it) Universita
More information